Reviva Q1 Earnings, Patent, Nasdaq Delisting
Analysis based on 6 articles · First reported May 13, 2026 · Last updated May 13, 2026
Reviva Pharmaceuticals Holdings' stock is likely to experience volatility due to its transition from Nasdaq-100 to the OTCQB Venture Market, which typically has lower liquidity. The positive financial results and strategic moves to extend patent life for brilaroxazine could provide some upside, but the market will closely watch the United States — Food and Drug Administration's feedback on the new drug form.
Reviva Pharmaceuticals Holdings reported its first-quarter 2026 financial results, showing a reduced net loss of $3.2 million and an increase in cash and cash equivalents to $22.2 million. The company also announced key business highlights, including the filing of a provisional patent application for a new form of brilaroxazine, aiming to extend commercial exclusivity through 2046. Reviva Pharmaceuticals Holdings is awaiting feedback from the United States — Food and Drug Administration on the use of this new form in its RECOVER-2 Phase 3 trial for schizophrenia, with patient enrollment expected to begin in Q3 2026. Additionally, the company completed a $10.0 million public equity offering and announced its common stock will transition from Nasdaq-100 to the OTCQB Venture Market on May 14, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard